INTRODUCTION: clinical guidelines recommend to identify and treat people at high risk of fracture. METHODS: we have carried out a simulation concerning pharmaco-economic issues in the treatment of severe osteoporosis and particularly those people with previous femoral fragility fractures, assuming that only 13.1% of hip fractured patients had started a proper antifracture therapy, as shown by the analysis of the Tuscany regional database. RESULTS: Annual costs sustained by the Italian healthcare system for treating hip fractured patients all over Italy have been estimated to range from 2 560 000 in year 2000 to 3 291 750 in year 2005, representing only 0,3% of the overall costs sustained because of hip fractures in Italy. CONCLUSIONS: Sixty percent of the pharmacological costs can be considered as ineffective from a therapeutic point of view because patients were assuming their drugs only for 6 months. There is a need for specific codification of osteoporotic fragility fractures at hospital admissions and for implementing regional strategies aimed to reduce hip re-fractures by increasing the number of patients on treatment and incrementing adherence to treatment.
INTRODUCTION: clinical guidelines recommend to identify and treat people at high risk of fracture. METHODS: we have carried out a simulation concerning pharmaco-economic issues in the treatment of severe osteoporosis and particularly those people with previous femoral fragility fractures, assuming that only 13.1% of hip fracturedpatients had started a proper antifracture therapy, as shown by the analysis of the Tuscany regional database. RESULTS: Annual costs sustained by the Italian healthcare system for treating hip fracturedpatients all over Italy have been estimated to range from 2 560 000 in year 2000 to 3 291 750 in year 2005, representing only 0,3% of the overall costs sustained because of hip fractures in Italy. CONCLUSIONS: Sixty percent of the pharmacological costs can be considered as ineffective from a therapeutic point of view because patients were assuming their drugs only for 6 months. There is a need for specific codification of osteoporotic fragility fractures at hospital admissions and for implementing regional strategies aimed to reduce hip re-fractures by increasing the number of patients on treatment and incrementing adherence to treatment.
Authors: E S Siris; S K Brenneman; E Barrett-Connor; P D Miller; S Sajjan; M L Berger; Y-T Chen Journal: Osteoporos Int Date: 2006-01-04 Impact factor: 4.507
Authors: P Piscitelli; G Iolascon; F Gimigliano; M Muratore; P Camboa; O Borgia; B Forcina; F Fitto; V Robaud; G Termini; G B Rini; E Gianicolo; A Faino; M Rossini; S Adami; A Angeli; A Distante; S Gatto; R Gimigliano; G Guida Journal: Osteoporos Int Date: 2006-10-24 Impact factor: 4.507
Authors: Sheryl Zimmerman; William G Hawkes; J Richard Hebel; Kathleen M Fox; Eva Lydick; Jay Magaziner Journal: Arch Phys Med Rehabil Date: 2006-03 Impact factor: 3.966
Authors: P Piscitelli; F Gimigliano; S Gatto; A Marinelli; A Gimigliano; P Marinelli; G Chitano; M Greco; L Di Paola; E Sbenaglia; M Benvenuto; M Muratore; E Quarta; F Calcagnile; G Colì; O Borgia; B Forcina; F Fitto; A Giordano; A Distante; M Rossini; A Angeli; A Migliore; G Guglielmi; G Guida; M L Brandi; R Gimigliano; G Iolascon Journal: Osteoporos Int Date: 2009-10-07 Impact factor: 4.507